Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
26/08/2025
The yield on the 10-year Japanese government bond has risen to 1.62%, its highest level since October 2008.
Latest
3 m ago
The yield on the 30-year US Treasury bond continued to decline, rising 5 basis points to 4.94%.
3 m ago
SAIC Group's joint brand Wuling and MG's first joint experiential center abroad is located in Indonesia.
3 m ago
The UK 30-year government bond yield rose by 7.6 basis points to 5.624%, reaching a new high since August 19. The UK 2-year government bond yield increased by 6 basis points to 4.008%.
4 m ago
The French CAC 40 index continued its decline from Monday, with the drop widening to 1.9%.
4 m ago
Gilead Sciences announced on Tuesday that its once-yearly injectable drug for HIV prevention has received marketing approval from the European Commission. The drug, known as lenacapavir, will be marketed under the brand name Yeytuo in Europe. The drug was approved by US regulators in June for sale in the US under the name Yeztugo. The approval by the European Commission applies to the 27 EU member states, as well as Norway, Iceland, and Liechtenstein. Before providing the drug to patients, Gilead will need to negotiate pricing and reimbursement terms with the healthcare systems of each country. Analysts predict that annual sales of this drug will exceed $4 billion by 2029. The approval by the European Commission allows for the use of this drug as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection through sexual transmission for adults and adolescents at high risk of infection with the deadly virus.
See all latest
